2-(Dimethylamino)-2-phenylbutan-1-ol
CAS : 39068-94-5
Ref. 3D-PBA06894
1g | Arrêté | ||
5g | Arrêté | ||
10g | Arrêté | ||
100mg | Arrêté | ||
250mg | Arrêté | ||
500mg | Arrêté |
Informations sur le produit
- 2-(Dimethylamino)-2-Phenylbutan-1-Ol
- 2-(Dimethylamino)-2-phenylbutanol
- 2-(N,N-Dimethylamino)-2-phenylbutanol
- Benzeneethanol, β-(dimethylamino)-β-ethyl-
- beta-(Dimethylamino)-beta-ethylphenethyl alcohol
- β-(Dimethylamino)-β-ethylbenzeneethanol
2-(Dimethylamino)-2-phenylbutan-1-ol (DMAPB) is a metabolite of the drug trimebutine, which is used for the treatment of biliary tract inflammation. DMAPB is metabolized by hydrolysis and oxidation to form an alkyl ester and a carboxylic acid. DMAPB has been shown to be rapidly eliminated from the body with a half-life of about 1 hour. There are no pharmacokinetic studies in humans, but pharmacokinetic parameters have been determined in rats. The major metabolic pathway for DMAPB is hydrolysis by alkaline phosphatase, which produces DMABA and phenylacetic acid. The major route of elimination is through urine, with little metabolism into other compounds. The kinetic profile of DMAPB was examined by liquid chromatography coupled with mass spectrometry and gas chromatography/mass spectrometry methods. Parameters such as the A